{"id":"NCT02226198","sponsor":"AstraZeneca","briefTitle":"A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (Aged 6 to <18 Years) With Homozygous Familial Hypercholesterolemia (HoFH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11","primaryCompletion":"2015-07","completion":"2015-07","firstPosted":"2014-08-27","resultsPosted":"2016-07-04","lastUpdate":"2016-07-04"},"enrollment":20,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Homozygous Familial Hypercholesterolemia (HoFH)"],"interventions":[{"type":"DRUG","name":"Rosuvastatin 20mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rosuvastatin","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to establish the efficacy, safety and tolerability of rosuvastatin in children and adolescents with homozygous familial hypercholesterolemia.","primaryOutcome":{"measure":"LDL-Cholesterol (mg/dL)","timeFrame":"Samples taken on Day 42 (week 6) and on day 84 (week 12)","effectByArm":[{"arm":"C-FAS Rosuvastatin","deltaMin":396,"sd":195.99},{"arm":"C-FAS Placebo","deltaMin":481.4,"sd":184.9}],"pValues":[{"comp":"OG000 vs OG001","p":"0.005"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":9,"countries":["Belgium","Canada","Denmark","Israel","Malaysia","Netherlands","Taiwan"]},"refs":{"pmids":["28838366"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":11},"commonTop":["Influenza like illness","Peripheral swelling","Abdominal pain upper","Influenza","Nasopharyngitis"]}}